SBIR / STTR #DHA26BZ01-DV005

DHA SBIR Solicitation: Development of Small Molecule Antifungal Therapeutics for Human Use (Direct to Phase II)

The Defense Health Agency (DHA) is seeking small business proposals for the research and development of innovative medical technologies, with a focus on antifungal therapeutics for human use under the SBIR program. - Government Buyer: - Defense Health Agency (DHA), SBIR Program Management Office - Products/Services Requested: - Research and development of small molecule antifungal compounds for safe use in human patients - Must demonstrate broad-spectrum activity against pathogens such as Fusarium, Aspergillus, Candida auris, and Mucorales - Compounds should have nanomolar antifungal activity and cytotoxicity comparable to or better than Amphotericin B - Emphasis on in vitro and in vivo efficacy, stability in austere conditions, and a regulatory strategy for FDA clearance - Additional SBIR topics (for context): - Shelf-stable canine whole blood product or substitute - Traumatic brain injury detection and treatment for Military Working Dogs - Environmental exposure detection and decontamination for Military Working Dogs - Wearable device for detecting and treating viral/bacterial infections - Quantities: - Single R&D effort for each topic; no specific production quantities - Unique/Notable Requirements: - Direct to Phase II SBIR solicitation (no Phase I required for this topic) - Proposals must address FDA clearance pathway and demonstrate compound stability in challenging environments - CMMC Level 1 required for Phase I, Level 2 for Phase II - Open only to small businesses with strong R&D capabilities - Focus on solutions for military operational medicine and drug-resistant fungal infections - No specific OEMs or commercial vendors are named in the solicitation.

Description

This solicitation seeks proposals for the development of small molecules with antifungal properties suitable for safe use in human patients, progressing directly to Phase II. The project aims to develop safe antifungal small molecules for human use. The solicitation is open and accepting proposals, with a response due date of July 31, 2016. Questions must be submitted by July 15, 2016.

View original listing